Insider Trading Arrangements [Line Items] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Less: accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Accumulated other comprehensive loss Acquired Finite-Lived Intangible Assets [Line Items] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Additional paid-in capital Additional Paid in Capital Amortization of intangible assets Amortization of Intangible Assets Consolidated Balance Sheets [Abstract] Net income (loss) per common share - basic (in dollars per share) Earnings Per Share, Basic Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Cash, Cash Equivalents, and Restricted Cash Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block] Cash decrease upon deconsolidation of subsidiaries Cash Divested from Deconsolidation Interest paid Interest Paid, Excluding Capitalized Interest, Operating Activities Valuation allowance increase (decrease) Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Accrued interest Accounts payable Increase (Decrease) in Accounts Payable, Trade Changes in assets and liabilities, net of effects from acquisition and divestiture: Increase (Decrease) in Operating Capital [Abstract] Accrued expenses Increase (Decrease) in Accrued Liabilities Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Common stock, shares issued (in shares) Common Stock, Shares, Issued Common stock, shares outstanding (in shares) Number of shares acquired (in shares) Common shares, par value $0.0000000341740141 per share, 7,000,000,000 shares authorized and 806,677,954 and 760,143,393 shares issued and outstanding at March 31, 2024 and 2023, respectively Common Stock, Value, Issued Current taxes [Abstract] Current Income Tax Expense (Benefit), Continuing Operations [Abstract] Deferred taxes [Abstract] Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract] Components of Deferred Tax Assets (Liabilities) [Abstract] Income Tax Expense (Benefit) [Abstract] Comprehensive income (loss) attributable to Roivant Sciences Ltd. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Computers [Member] Computer Equipment [Member] Cost of Revenues Cost of Goods and Service [Policy Text Block] Current tax expense Current Income Tax Expense (Benefit) Total current liabilities Liabilities, Current Current liabilities: Liabilities, Current [Abstract] Carrying balance Principal amount Long-Term Debt, Gross Face amount Fair value of long-term debt Debt issued by Dermavant to NovaQuest Debt Instrument, Fair Value Disclosure Reduction in exit fee Debt Instrument, Fee Amount Frequency of periodic payment Interest rate Debt Instrument, Interest Rate, Stated Percentage Debt Instrument [Line Items] Schedule of Long-term Debt Instruments [Table] Deferred tax benefit Deferred Income Tax Expense (Benefit) Deferred tax assets [Abstract] Deferred Tax Assets, Gross [Abstract] Subtotal Deferred Tax Assets, Gross Capitalized research and development Total deferred tax assets/(liabilities) Deferred Tax Assets, Net Net operating loss Deferred Tax Assets, Operating Loss Carryforwards Other assets Deferred Tax Assets, Other Research tax credits Deferred Tax Assets, Tax Credit Carryforwards, Research Share-based compensation Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost Valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Deferred tax liabilities [Abstract] Deferred Tax Liabilities, Gross [Abstract] Other liabilities Deferred Tax Liabilities, Other Deferred revenue Deferred Revenue, Current Liability instruments measured at fair value Derivative Instruments Not Designated as Hedging Instruments, Liability, at Fair Value Net income (loss) per common share - diluted (in dollars per share) Earnings Per Share, Diluted Discontinued Operations Equity Method Investments Equity Method Investments and Joint Ventures Disclosure [Text Block] Principles of Consolidation Consolidation, Policy [Policy Text Block] Disposal Group Name [Domain] Disposal Group Name [Axis] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Disposal Groups, Including Discontinued Operations [Table] Total income tax expense Effective Income Tax Rate Reconciliation, Percent Reconciliation of Income Tax Provision/(Benefit), Percent [Abstract] Effective Income Tax Rate Reconciliation, Percent [Abstract] Valuation allowance Income tax benefit at Bermuda statutory rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent Permanent disallowed IPR&D Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent Nondeductible executive compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Other Research tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent Share-based compensation expense Share-Based Payment Arrangement, Expense RSL ESPP [Member] Share-based compensation Share-Based Payment Arrangement, Noncash Expense Share-Based Compensation [Abstract] Share-Based Payment Arrangement, Noncash Expense [Abstract] Number of shares issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Laboratory and Other Equipment [Member] Ownership percentage Equity Method Investment, Ownership Percentage Foreign Currency Foreign Currency Transactions and Translations Policy [Policy Text Block] Furniture and Fixtures [Member] Furniture and Fixtures [Member] Change in fair value of investments Gain (Loss) on Investments Intangible Assets, Net Intangible Assets, Finite-Lived, Policy [Policy Text Block] Gross profit Acquired In-Process Research and Development Expenses In Process Research and Development, Policy [Policy Text Block] Condensed Consolidated Statements of Operations [Abstract] Summarized Consolidated Financial Information [Abstract] Income (loss) from continuing operations, net of tax Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent Income (loss) from continuing operations (in dollars per share) Income (Loss) from Continuing Operations, Per Diluted Share Income (loss) from continuing operations (in dollars per share) Income from discontinued operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Income from discontinued operations, net of tax (in dollars per share) Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share Income from discontinued operations, net of tax operations (in dollars per share) Income Taxes Income Tax Disclosure [Text Block] Interest and penalties related to unrecognized tax benefits Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Income Taxes Income Tax, Policy [Policy Text Block] Reconciliation of Income Tax Provision/(Benefit) , Amount [Abstract] Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract] Foreign rate differential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Income tax expense/(benefit) at Bermuda statutory tax rate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount Permanent disallowed IPR&D Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount Nondeductible executive compensation Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount Other Effective Income Tax Rate Reconciliation, Other Adjustments, Amount Research tax credits Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount Income taxes paid Income Taxes Paid, Net Income tax receivable Intangible assets, net Net book value Intangible Assets, Net (Excluding Goodwill) Gross amount Finite-Lived Intangible Assets, Gross Recognized Intangible Assets [Abstract] Interest expense Interest Expense Interest receivable Inventory Inventory, Net Inventory Inventory, Policy [Policy Text Block] Investments Investment, Policy [Policy Text Block] Total liabilities Liabilities Total liabilities and shareholders' equity Liabilities and Equity Liabilities and Shareholders' Equity Liabilities and Equity [Abstract] Current portion of long-term debt (includes $6,000 and $26,940 accounted for under the fair value option at March 31, 2024 and 2023, respectively) Less: current portion Long-Term Debt, Current Maturities Thereafter Long-Term Debt, Maturity, after Year Five 2025 Long-Term Debt, Maturity, Year One 2029 Long-Term Debt, Maturity, Year Five 2028 Long-Term Debt, Maturity, Year Four 2027 Long-Term Debt, Maturity, Year Three 2026 Long-Term Debt, Maturity, Year Two Total long-term debt, net Long-term debt, net of current portion (includes $204,371 and $180,700 accounted for under the fair value option at March 31, 2024 and 2023, respectively) Total debt, net Long-Term Debt Noncontrolling interests Equity, Attributable to Noncontrolling Interest Money Market Funds [Member] Related Party, Type [Axis] Cash Flow from Discontinued Operations [Abstract] Net Cash Provided by (Used in) Discontinued Operations [Abstract] Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net income (loss) attributable to Roivant Sciences Ltd. Net Income (Loss) Attributable to Parent Proceeds from issuance of the Company's common stock under employee stock purchase plan Net operating losses Operating Loss Carryforwards Income (loss) from operations Loss from operations Revenues: Other comprehensive loss: Other Comprehensive Income (Loss), Tax [Abstract] Other current assets Total other current assets Other Assets, Current Other Other Sundry Liabilities, Current Other Payments for (Proceeds from) Other Investing Activities Other expense (income), net Other Nonoperating Income (Expense) Prepaid expenses Private Placement [Member] Proceeds from sale of subsidiary interests Net proceeds of common stock Proceeds from issuance of the Company's common shares, net of issuance costs paid Proceeds from Issuance of Common Stock Purchase of equity Proceeds from Lines of Credit Proceeds from exercise of the Company's and subsidiary stock options Property and equipment, net Property, Plant and Equipment, Net Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Trade receivables, net Related Party, Type [Domain] Payments related to long-term debt Repayments of Long-Term Debt Contributions from issuance of shares Research and Development Expenses Research and Development Expense, Policy [Policy Text Block] Retained earnings / (accumulated deficit) Retained Earnings (Accumulated Deficit) Sale of Stock [Domain] Purchase price (in dollars per share) Sale price (in dollars per share) Recognized Intangible Assets Significant Equity Method Investments Equity Method Investments [Table Text Block] Long-Term Debt, Net Cash Flow from Discontinued Operations Selling, general and administrative (includes $164,841 and $186,603 of share-based compensation expense for the years ended March 31, 2024 and 2023, respectively) Selling, general and administrative expense Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Non-vested balance, beginning (in shares) Non-vested balance, ending (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Non-vested balance, beginning (in dollars per share) Non-vested balance, ending (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Unrecognized compensation expense Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Service-vested (in shares) Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Fair value of CVARs that service-vested Service-vested (in dollars per share) Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Common shares available for future grants (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Outstanding, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Options outstanding, beginning balance (in shares) Options outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding, beginning balance (in dollars per share) Outstanding, beginning balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Options exercisable at September 30, 2023 (in shares) Exercisable, period end (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Expected dividend yield Expected risk free interest rate Expected stock price volatility Award Type [Domain] Award Type [Domain] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Consolidated Statements of Cash Flows [Abstract] Consolidated Statements of Comprehensive Income (Loss) [Abstract] Consolidated Statements of Shareholders' Equity and Redeemable Noncontrolling Interest [Abstract] Share-Based Compensation Share-Based Payment Arrangement [Policy Text Block] Shareholders' equity: Equity, Attributable to Parent [Abstract] Shareholders' Equity Description [Abstract] Class of warrant outstanding (in shares) Shareholders' Equity Equity [Text Block] Subsequent Event Type [Axis] Subsequent Event [Line Items] Subsequent Event [Table] Subsequent Event Type [Domain] Sale of Stock [Axis] Supplemental disclosure of cash paid: Supplemental Cash Flow Information [Abstract] Research tax credit carryforwards Tax Credit Carryforward, Amount Total current assets Assets, Current Current assets: Assets, Current [Abstract] Warrant [Member] Weighted average shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted average shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Investor [Member] Common Stock [Member] Common Shares [Member] Common Stock [Member] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Software [Member] Software Development [Member] Research and development (includes $34,595 and $30,914 of share-based compensation expense for the years ended March 31, 2024 and 2023, respectively) Research and development expense Total assets Assets Intangible Assets Other Current Liabilities [Abstract] Other Liabilities, Current [Abstract] Other current liabilities Total other current liabilities Other Liabilities, Current Other liabilities Other Liabilities, Noncurrent Financial Instruments [Domain] Type of Restructuring [Domain] Contract Termination [Member] Share-Based Compensation Share-Based Payment Arrangement [Text Block] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Discontinued Operations [Member] Discontinued Operations [Member] Statement [Table] Statement [Table] Antidilutive Securities, Name [Domain] Investments measured at fair value Retained investment Investment Aggregate Fair Value Assets Assets [Abstract] Statement [Line Items] Statement [Line Items] Changes in Fair Value of the Level 3 Assets Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Beginning Balance Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Changes in Fair Value of the Level 3 Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Changes in fair value of debt and liability instruments, included in net loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Shareholders' Equity [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Annual Maturities of including Exit Fee [Abstract] Class of Stock [Domain] Commitments [Abstract] Long-Term Purchase Commitment [Table] Category of Item Purchased [Axis] Long-Term Purchase Commitment, Category of Item Purchased [Domain] Long-Term Purchase Commitment [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Other assets Other Assets, Noncurrent Operating expenses: Operating Expenses [Abstract] Total operating expenses Operating Expenses Net income (loss) per common share, basic: Net income (loss) per common share, diluted: Potentially dilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive Securities [Axis] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Net Income (Loss) per Common Share [Abstract] Potentially Dilutive Common Stock Equivalents Excluded from Computation of Diluted Net Income (Loss) per Common Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Net (Loss) Income per Common Share [Abstract] Earnings Per Share, Diluted, Other Disclosure [Abstract] Other liabilities Increase (Decrease) in Other Operating Liabilities Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Table] Schedule of Equity Method Investments [Line Items] Schedule of Equity Method Investments [Line Items] Class of Stock [Axis] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Carrying Balance [Abstract] Outstanding Debt Obligations [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Property, Plant and Equipment [Line Items] Common shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Shareholders' equity attributable to Roivant Sciences Ltd. Equity, Attributable to Parent Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount Income tax expense Total income tax expense Income Tax Expense (Benefit) Total liabilities at fair value Fair value liability Equity Components [Axis] Equity Components [Axis] Additional Paid-in Capital [Member] Additional Paid-in Capital [Member] (Accumulated Deficit) / Retained Earnings [Member] Retained Earnings [Member] Accumulated Other Comprehensive Loss [Member] AOCI Attributable to Parent [Member] Equity Component [Domain] Equity Component [Domain] Stock Options [Member] Share-Based Payment Arrangement, Option [Member] Forfeited/Canceled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Forfeited/Canceled (in dollars per share) Long-Term Debt and Loan Commitment Long-Term Debt [Text Block] Selling, General and Administrative Expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] Issuance of the Company's common shares under employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Common shares issued (in shares) Issuance of the Company's common shares under employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Contingencies Commitments and Contingencies, Policy [Policy Text Block] Non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Number of Shares [Roll Forward] Weighted-Average Remaining Contractual Term [Abstract] Capped Value Appreciation Rights [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Assumptions [Abstract] Net Income (Loss) per Common Share Earnings Per Share [Text Block] Net income (loss) Net income (loss) Net loss Net loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Weighted average shares outstanding: Income (loss) from continuing operations, net of tax Income (Loss) from continuing operations, net of tax Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Amounts attributable to Roivant Sciences Ltd.: Income from discontinued operations, net of tax Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent Depreciation and amortization Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive loss attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Ending balance Beginning balance Total shareholders' equity Equity, Including Portion Attributable to Noncontrolling Interest Noncontrolling Interests [Member] Noncontrolling Interest [Member] Class of Stock [Line Items] Class of Stock [Line Items] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Leases [Abstract] Commitments and contingencies (Note 14) Commitments and Contingencies Gain on deconsolidation of subsidiaries Gain on deconsolidation of subsidiaries Gain on deconsolidation of subsidiaries Deconsolidation of subsidiary Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount Adjustments to reconcile net income (loss) to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Carrying Balance of Debt Issued [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Total accrued expenses Accrued Liabilities, Current Compensation-related expenses Employee-related Liabilities, Current Other expenses Other Accrued Liabilities, Current Income tax payable Accrued Expenses [Abstract] Accrued Liabilities, Current [Abstract] Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Income (loss) before income taxes [Abstract] Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest [Abstract] Income (loss) from continuing operations before income taxes Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Other Current Assets [Abstract] Prepaid Expense and Other Assets, Current [Abstract] Increase (Decrease) in Temporary Equity [Roll Forward] Total assets at fair value Assets, Fair Value Disclosure Liabilities at fair value Liabilities, Fair Value Disclosure Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Recurring [Member] Fair Value, Recurring [Member] Proceeds from exercise of the Company's warrants Fair value of liability instrument issued Asset Class [Domain] Product revenue, net [Member] Product [Member] Description of Business and Liquidity Business Description and Basis of Presentation [Text Block] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Balance at end of period Balance at beginning of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Proceeds from Issuance of Debt Proceeds from Issuance of Debt Asset Class [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Measurement Frequency [Axis] Measurement Frequency [Axis] Annual Maturities of Long-Term Debt Components of Deferred Tax Assets (Liabilities) Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Income Tax Expense Reconciliation of Income Tax Expense/(Benefit) Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Income/(Loss) Before Income Taxes and Related Expense (Benefit) Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Assets and Liabilities are Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Cash, Cash Equivalents, and Restricted Cash Schedule of Cash and Cash Equivalents [Table Text Block] Commitments and Contingencies [Abstract] Income Taxes [Abstract] Intangible Assets [Abstract] Fair Value Measurements [Abstract] Subsequent Events Long-Term Debt [Abstract] Schedule of Fair Value Assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Total long-term debt, net Long term debt accounted under fair value option Long-Term Debt, Fair Value Less: current portion Current portion of long-term debt accounted for under fair value option Short-Term Debt, Fair Value Share-Based Compensation [Abstract] Use of Estimates Use of Estimates, Policy [Policy Text Block] Assets: [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Calculation Using Significant Unobservable Inputs Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Liabilities: [Abstract] Recurring Fair Value Measurements [Abstract] Research and Development Expense [Member] Restructuring Type [Axis] Summary of Significant Accounting Policies [Abstract] Equity Method Investments [Abstract] Discontinued Operations [Abstract] Subsequent Events [Abstract] Other Other Noncash Income (Expense) Certain Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Other current assets Increase (Decrease) in Other Current Assets Other assets Increase (Decrease) in Other Noncurrent Assets Unrealized Loss (Gain) on Investment Unrealized Gain (Loss) on Investments Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Exercisable, aggregate intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other Current Assets Capped Value Appreciation Right , Weighted Average Grant Date Fair Value [Abstract] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Unrecognized compensation expense Share price (in dollars per share) Purchase price per share (in dollars per share) Financial Instrument [Axis] Ending balance Beginning balance Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Average Exercise Price [Roll Forward] Granted (in dollars per share) Exercised (in dollars per share) Share Repurchase Program [Axis] Share Repurchase Program [Domain] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] Award Type [Axis] Award Type [Axis] Subsequent Event [Member] Income Statement Location [Axis] Income Statement Location [Domain] Recently Adopted/ Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Concentrations Concentration Risk, Credit Risk, Policy [Policy Text Block] Intangible assets Deferred Tax Assets, Goodwill and Intangible Assets Estimated useful lives Property, Plant and Equipment, Useful Life Future amortization expense, 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Future amortization expense, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Future amortization expense, 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Future amortization expense, 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four Future amortization expense, 2029 Future amortization expense, thereafter Outstanding, weighted-average remaining contractual term Exercisable, weighted-average remaining contractual term Expected term, in years Remaining weighted-average service period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Number of operating segment Number of Operating Segments Number of reporting segment Number of Reportable Segments Selling, General and Administrative Expense [Member] Selling, General and Administrative Expenses [Member] Research tax credit carryforwards expiration date Tax Credit Carryforward, Expiration Date Changes in fair value of investment in Datavant, included in net loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Total other comprehensive loss Other Comprehensive Income (Loss), Net of Tax Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Cost of Revenues [Member] Other Investment [Member] Other Investment Companies [Member] Issuance of subsidiary preferred shares Net operating losses expiration date Operating Loss Carryforwards, Expiration Date Gain on sale of Telavant net assets Gain (Loss) on Disposition of Assets Warrants issued (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Grant date fair value of options vested Fair value of stock options vested Other Current Liabilities Debt instrument, term Financial liabilities at fair value Financial Liabilities Fair Value Disclosure Award Date [Axis] Award Date [Domain] Related Party Transaction [Axis] Related Party Transaction [Domain] Purchase certain quantities of inventory over period Common stock repurchase authorized amount Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Disposal Group Classification [Axis] Disposal Group Classification [Domain] Less: unamortized issuance costs Less: unamortized discount and debt issuance costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Operating Lease Cost [Abstract] Operating lease cost Operating Lease, Cost Short-term lease cost Short-Term Lease, Cost Variable lease cost Variable Lease, Cost Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Revenue [Abstract] Revenue Revenue from Contract with Customer [Text Block] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Maturities of Operating Lease Liabilities [Abstract] Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Revenue, net Revenue Cash, Cash Equivalents, and Restricted Cash [Abstract] Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Restricted Cash Restricted cash (included in "Other current assets") Restricted Cash, Current Restricted cash (included in "Other assets") Effect of exchange rate changes on cash, cash equivalents, and restricted cash Net change in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, cash equivalents and restricted cash at end of period Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash paid for operating lease liabilities Operating Lease, Payments Payments on principal portion of finance lease obligations Finance Lease, Principal Payments Operating lease right-of-use assets obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Total lease payments Lessee, Operating Lease, Liability, to be Paid Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Five 2025 Lessee, Operating Lease, Liability, to be Paid, Year One 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Maturities of Operating Lease Liabilities Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Total lease liabilities Operating Lease, Liability Operating lease liabilities Operating Lease, Liability, Current Operating lease liabilities, noncurrent Operating Lease, Liability, Noncurrent Components of Operating Lease Expense Lease, Cost [Table Text Block] Leases Lessee, Leases [Policy Text Block] Leases Lessee, Operating Leases [Text Block] Measurement Input Type [Axis] Term (in years) [Member] Measurement Input, Expected Term [Member] Volatility [Member] Measurement Input, Price Volatility [Member] Risk-free Rate [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input Type [Domain] Private placement warrants, measurement input Warrants and Rights Outstanding, Measurement Input Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Tax deficiencies (excess tax benefits) from stock-based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Tax deficiencies (excess tax benefits) from stock-based compensation Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Warrants expiration period Private placement warrants, term Fair Value, Asset, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration] Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee [Domain] Non-cash lease expense Operating lease liabilities Increase (Decrease) in Operating Lease Liability Asset Acquisition [Abstract] Asset Acquisition [Abstract] Asset Acquisition [Table] Asset Acquisition [Line Items] Fair value of consideration transferred Asset Acquisition, Consideration Transferred Derivative Liability, Statement of Financial Position [Extensible Enumeration] Title of Individual [Domain] Investment, Name [Domain] Independent Directors [Member] Chief Financial Officer [Member] Scenario [Domain] Forecast [Member] Scenario [Axis] Investment, Name [Axis] Geographical [Domain] Geographical [Domain] Geographical [Axis] Geographical [Axis] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Counterparty Name [Axis] Counterparty Name [Domain] Title of Individual [Axis] Consolidated Entities [Axis] Consolidated Entities [Domain] Product and Service [Domain] Product and Service [Axis] Bermuda [Member] BERMUDA Switzerland [Member] SWITZERLAND United Kingdom [Member] UNITED KINGDOM United States [Member] UNITED STATES Cover [Abstract] Document Type Document Annual Report Document Transition Report Document Financial Statement Error Correction [Flag] Entity Interactive Data Current Amendment Flag ICFR Auditor Attestation Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Shell Company Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Public Float Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Common Stock, Shares Outstanding Auditor Name Auditor Location Auditor Firm ID Noncontrolling interests that are mandatorily redeemable upon a certain date or event occurring. Redeemable Noncontrolling Interest [Member] Redeemable Noncontrolling Interest [Member] The number of shares issued in connection with equity incentive plans and tax withholding payments. Stock Issued During Period, Shares, in Connection with Equity Incentive Plans and Tax Withholding Payments Issuance of common shares in connection with equity incentive plans and tax withholding payments (in shares) Value of stock issuance of common shares and other consideration for acquisition. Stock Issued During Period, Common Shares and Other Consideration for Acquisition, Value Issuance of the Company's common shares and other consideration for an acquisition The amount of the increase in or (reduction or elimination) during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest. Noncontrolling Interest, Increase Decrease from Deconsolidation Deconsolidation of subsidiaries Dividend declared by subsidiary. Dividend Declared by Subsidiary Dividend declared by subsidiary The amount net common shares issued of subsidiary to the company, net of issuance costs. Issuance of Subsidiary Common Shares to the Company Net Issuance Costs, Value Issuance of subsidiary common shares, net of issuance costs The amount net common shares issued of subsidiary to the company and cash contributions to majority-owned subsidiaries. Issuance of Subsidiary Common Shares to the Company and Capital Contributions to Subsidiaries Issuance of subsidiary common shares to the Company and cash contributions to majority-owned subsidiaries The value of stock issued in connection with equity incentive plans and tax withholding payments. Stock Issued During Period Value In Connection With Equity Incentive Plans And Tax Withholding Payments Issuance of common shares in connection with equity incentive plans and tax withholding payments The number of stock issuance of common shares and other consideration for acquisition during the period. Stock Issued During Period, Common Shares and Other Consideration for Acquisition, Shares Issuance of the Company's common shares and other consideration for an acquisition (in shares) Number of stock issued during the period net of issuance costs. Stock Issued During Period, Shares, Net Issuance Costs Issuance of the Company's common shares, net of issuance costs (in shares) Number of shares issued common share related to settlement of warrants shares. Stock Issued During Period, Value, Common Share Related to Settlement of Warrants Shares Issuance of the Company's common shares related to settlement of warrants (in shares) Amount of increase to additional paid-in capital (APIC) and Noncontrolling Interest for recognition of cost for award under share-based payment arrangement. APIC and Noncontrolling Interest, Share-Based Payment Arrangement, Increase for Cost Recognition Share-based compensation Aggregate change in value issuance of the company's common share related to settlement of warrants value. Stock Issued During Period, Value, Common Share Related to Settlement of Warrants Value Issuance of the Company's common shares related to settlement of warrants The value of stock issued in connection with equity incentive plans net of forfeitures and tax withholding payments. Stock Issued During Period, Value, in Connection with Equity Incentive Plans Net of Forfeitures and Tax Withholding Payments Issuance of the Company's common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments Number of common shares issuance of subsidiary to the Company. Issuance of Subsidiary Common Shares to the Company, Shares Issuance of subsidiary common shares, net of issuance costs (in shares) Stock issued during the period value, net of issuance costs. Stock Issued During Period, Value, Net Issuance Costs Issuance of the Company's common shares, net of issuance costs The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the disposition of subsidiary. Noncontrolling Interest, Increase Decrease from Disposition Disposition of Telavant The amount of subsidiary stock issued as a result of stock options exercised. Stock Issued During Period, Value, Subsidiary, Stock Options Exercised Subsidiary stock options exercised The amount of common shares issued related to settlement of transaction consideration. Stock Issued During Period, Value, Common Shares Related to Settlement of Transaction Consideration Issuance of the Company's common shares related to settlement of transaction consideration The number of shares increase to additional paid-in capital (APIC) and Noncontrolling Interest for recognition of cost for award under share-based payment arrangement. APIC And Noncontrolling Interest Share Based Payment Arrangement Increase For Cost Recognition, Shares Share-based compensation expense (in shares) The number of shares issued in connection with equity incentive plans net of forfeitures and tax withholding payments. Stock Issued During Period, Shares, in Connection with Equity Incentive Plans Net of Forfeitures and Tax Withholding Payments Issuance of the Company's common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments (in shares) The number of common shares issued related to settlement of transaction consideration. Stock Issued During Period, Shares, Common Shares Related to Settlement of Transaction Consideration Issuance of the Company's common shares related to settlement of transaction consideration (in shares) Represents the license, milestone, and other revenue. License, Milestone and Other Revenue [Member] License, milestone and other revenue [Member] Amount of gain (loss) on fair value of debt and liability instruments. Gain (Loss) on Fair Value of Debt and Liability Instruments Change in fair value of debt and liability instruments Interest income on nonoperating activities. Interest Income Interest income The total amount of operating cost and expense. Operating Costs Cost of revenues Amount of acquired in-process research and development expense. Acquired in Process Research and Development Expense Acquired in-process research and development Amount of gain (loss) on sale of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee. Gain (Loss) on Sale of Assets Gain on sale of Telavant net assets Gain on sale of net assets GSK Solutions Inc. is a cutting edge, no-nonsense cyber security company who provides security software, services, and consulting. GSK [Member] GSK [Member] The remaining minimum amount of purchase commitment related to agreements. Remaining Minimum Purchase Commitment Related to Agreement Remaining minimum purchase commitment related to agreement The remaining employee related liabilities current. Remaining Employee Related Liabilities Current Remaining employee related liabilities current The period to purchase additional batches of batoclimab, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Period to Purchase Additional Batches of Batoclimab Period to purchase additional batches of batoclimab Samsung Biologics is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea. Samsung Biologics Co., Ltd. [Member] Samsung [Member] The company approved a special one-time cash retention bonus award to its employees. Cash Bonus Program [Member] Cash Bonus Program [Member] The period of right to terminate the product service agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Period of Right to Terminate the Product Service Agreement Period of right to terminate the product service agreement Name of the acquiree. Dermavant [Member] Dermavant [Member] VTAMA/tapinarof (Dermavant) [Member] Name of the entity. HanAll Biopharma Co., Ltd. (Immunovant) [Member] The name of entity owned or controlled subsidiary. Priovant Therapeutics Inc [Member] Brepocitinib (Priovant Therapeutics, Inc.) [Member] Name of entity. Izana Biosciences Limited (Kinevant Ltd.) [Member] The maximum potential future milestone payment pursuant to certain key asset acquisition and license agreements. Maximum Potential Future Milestone Payments Potential material future milestone payments First milestone payable amount under remaining commercial milestones. First Milestone Payable Amount Under Remaining Commercial Milestones A revenue interest purchase and sale agreement between Dermavant and XYQ Luxco, NovaQuest. Revenue Interest Purchase and Sale Agreement with XYQ Luxco, NovaQuest [Member] Revenue Interest Purchase and Sale Agreement with XYQ Luxco, NovaQuest [Member] An senior secured credit facility entered by Dermavant and certain of its subsidiaries with XYQ Luxco S.A.R.L ("XYQ Luxco"),. Credit Facility with XYQ Luxco [Member] Credit Facility with XYQ Luxco [Member] An asset purchase funding agreement between Dermavant and NovaQuest Co-Investment Fund VIII, L.P (the "NovaQuest Agreement"). Funding Agreement with NovaQuest [Member] Funding Agreement with NovaQuest [Member] Description of Business and Liquidity [Abstract] Revenue Interest Purchase and Sale Agreement [Abstract] Revenue Interest Purchase and Sale Agreement [Abstract] The committed funding under revenue interest purchase and sale agreement (RIPSA). Committed Funding under RIPSA Royalties entitled to receive The committed funding under revenue interest purchase and sale agreement received. Committed Funding under Revenue Interest Purchase and Sale Agreement Received Committed funding under revenue interest purchase and sale agreement received The committed funding under revenue interest purchase and sale agreement. Committed Funding under Revenue Interest Purchase and Sale Agreement Face amount Funding Agreement with NovaQuest [Abstract] Funding Agreement with NovaQuest [Abstract] The maximum milestone payment offset amount. Maximum Milestone Payment Offset Amount Right to offset of commercial milestones payment The milestone payment due over six-year period. Milestone Payment Due Over Six Year Period Periodic payment The maximum milestone payment obligation. Maximum Milestone Payment Obligation Maximum milestone payment obligation Amount of quarterly payments made under the agreement. Debt Instrument, Quarterly Payments Made Quarterly payments made Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions. Lessee, Operating Lease, Disclosure [Table Text Block] Operating Lease Right-of-use Assets and Lease Liabilities Name of related party. Myovant Sciences Ltd. [Member] Myovant Sciences Ltd. [Member] RSL [Member] Myovant Transaction [Abstract] Myovant Transaction [Abstract] The maximum number of shares of Common Stock that such holder of Applicable Shares is entitled to purchase pursuant to an agreement. Number of Top-Up shares received Number of Top-Up shares received (in shares) Amount of cash inflow from the sale of Top-Up shares attributable to discontinued operations. Proceeds from Sale of Top-Up Shares, Discontinued Operations Proceeds from sale of Myovant Top-Up Shares Amount of cash outflow from gain (loss) on recovery of contingent consideration attributable to discontinued operations. Gain (Loss) on Recovery of Contingent Consideration, Discontinued Operations Gain on recovery of contingent consideration Number of Vants in which the entity has ownership interest. Number of Vants Number of Vants Amount of liability instruments measured at fair value. Liability Instruments Measured at Fair Value Liability instruments measured at fair value Disclosure of information about income taxes. Income Taxes [Table] It includes the greater china and united kingdom activity. Other [Member] Other [Member] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Income Taxes [Line Items] Certain Balance Sheet Components [Abstract] Amount of deferred tax liability attributable to taxable temporary differences from depreciation. Deferred Tax Liabilities, Depreciation Depreciation Amount of deferred tax liability attributable to taxable temporary differences from right of use assets. Deferred Tax Liabilities, Right-of-use Assets Right-of-use assets Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the lease liabilities. Deferred Tax Assets, Lease Liabilities Lease liabilities Recent Transactions [Abstract] The entire disclosure for recent transactions. Recent Transactions [Text Block] Recent Transactions Amount of other current assets classified as other. Other of Other Assets, Current Other Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to reversal of certain deferred tax assets. Effective Income Tax Rate Reconciliation, Reversal of Certain Deferred Tax Assets, Percent Reversal of certain deferred tax assets Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other permanent adjustments Effective Income Tax Rate Reconciliation, Other Permanent Adjustments, Percent Other permanent adjustments Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to significant shareholding exemption. Effective Income Tax Rate Reconciliation, Significant shareholding exemption, Percent Substantial shareholding exemption Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible/(nontaxable) changes in the fair value of investments and loss from equity method investment. Effective Income Tax Rate Reconciliation, Nondeductible/(nontaxable) Changes in Fair Value of Investments and Loss from Equity Method Investment Nondeductible/(nontaxable) changes in the fair value of investments and loss from equity method investments Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to reversal of certain deferred tax assets. Effective Income Tax Rate Reconciliation, Reversal of Certain Deferred Tax Assets, Amount Reversal of certain deferred tax assets Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to substantial shareholding exemption. Effective Income Tax Rate Reconciliation, Substantial Shareholding Exemption, Amount Substantial shareholding exemption Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other permanent adjustments. Effective Income Tax Rate Reconciliation, Other Permanent Adjustments, Amount Other permanent adjustments Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible/(nontaxable) changes in the fair value of investments and loss from equity method investment. Effective Income Tax Rate Reconciliation, Nondeductible/(Nontaxable) Changes in Fair Value of Investments and Loss from Equity Method Investment, Percent Nondeductible/(nontaxable) changes in the fair value of investments and loss from equity method investment Intangible Asset [Abstract] Intangible Assets [Abstract] Payment made during the period for achieving the milestone or milestones. Milestone Paid Milestone amount paid Amount of milestone payable. Milestone Payable Milestone payable The name of entity acquired intangibles assets. Welichem Biotech Inc [Member] The name of entity acquired intangibles assets. GlaxoSmithKline Intellectual Property Development Ltd. [Member] GSK [Member] The common shares aggregate offering price authorized remaining capacity to issue under equity offering program. Common Shares Aggregate Offering Price Authorized, Remaining Capacity Available Common shares aggregate offering price authorized, remaining capacity available The net cash inflow from the additional capital contribution to the entity. Net Proceeds from Issuance of Common Stock Net proceeds from sale of common stock Number of shares of stock issued and sold upon exercise of the underwriters option. Stock Issued and Sold Upon Exercise of the Underwriters Option Common stock, shares issued upon exercise of underwriter's options (in shares) The percentage ownership of a subsidiary. Ownership of Subsidiary Percentage Ownership of subsidiary Stock sold during period by selling shareholders. Stock Sold During Period by Selling Shareholders Stock sold during period by selling shareholders (in shares) The common shares aggregate offering price authorized to issue under equity offering program. Common Shares Offering Price Authorized Common shares aggregate offering price authorized Name of subsidiary. Immunovant, Inc. [Member] Immunovant, Inc. [Member] Number of additional shares of common stock option to purchase. Option to Purchase Additional Shares of Common Stock Option purchase additional shares of common stock (in shares) Offering of "at-the-market" shares as per equity distribution agreement. Equity Offerings at the Market [Member] At-the-Market Equity Offering Program[Member] Public offering in which the Common Stock is offered and sold on a firm commitment basis through one or more underwriters. Underwritten Public Offering [Member] Underwritten Public Offering [Member] The common shares sold by RSL. Sold by RSL [Member] Sold by RSL [Member] The common shares sold by selling shareholders. Sold by Selling Shareholders [Member] Sold by Selling Shareholders [Member] Roivant participation of Immunovant Stock offering [Member] Roivant participation of Immunovant Stock offering [Member] Number of new stock purchased during the period. Stock Purchased During Period by Entity, Shares Common shares purchased by RSL (in shares) The estimated net cash inflow from the additional capital contribution to the entity. Estimated Net Proceeds from Issuance of Common Stock Net proceeds of common stock An affiliate with whom the entity entered into a committed equity facility agreement. Cantor Fitzgerald Co. [Member] Cantor [Member] An affiliate with whom the entity entered into a sales agreement. Cowen and Company, LLC [Member] Cowen [Member] Cytovant [Member] Cytovant [Member] Cytovant [Member] Amount of tenant improvement allowance adjustment for operating lease. Lessee Operating Lease Liability Tenant Improvement Allowance Less: tenant improvement allowance Amount of present value adjustment for operating lease. Operating Lease Liability Present Value Adjustments Less: present value adjustment Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to research and development expenses, due within one year or the normal operating cycle, if longer. Accrued Research and Development Expenses, Current Research and development expenses Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to sales allowances, due within one year or the normal operating cycle, if longer. Accrued Sales Allowances Current Sales allowances Loan and Credit Agreements by Dermavant [Abstract] Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, debt instrument carrying amount including exit fee. Debt Instrument Carrying Amount including Exit Fee Total debt gross, including exit fee The amount of expenses associated with exit fee and end of term charge of debt instrument. Debt Instrument, Exit Fee and End of Term Charge Debt instrument exit fee and end of term charge Amount of expenses associated with exit fee of debt instrument. Debt Instrument, Exit Fee Exit fee Operating Leases [Abstract] a newly-formed subsidiary in-licensed certain intellectual property rights in exchange for a $14.0 million upfront cash payment. Newly-Formed Subsidiary [Member] SK Biopharmaceuticals Co., Ltd. ("SK Bio"), a subsidiary of SK Inc. SK Biopharmaceuticals Co Ltd [Member] Name of the entity. SK, Inc. [Member] Preferred financing in exchange for shares of VantAI's Series Spin Preferred Stock VantAI Preferred Financing [Member] The name of entity owned or controlled subsidiary. ProteoVant Sciences, Inc [Member] Proteovant [Member] Deconsolidation of Subsidiaries [Abstract] The cash outflow associated with the upfront cash payment during the period. Upfront Cash Payment Upfront Cash Payment Amount of milestone payment payable. Milestone Payment Payable Milestone payment payable Amount of asset acquisition research and development expense in-process. Asset Acquisition, Research and Development Expense in Process Acquired in process research and development expense Tabular disclosure of information related to the calculation of the gain on sale of assets. Schedule of Gain on Sale of Assets Calculation [Table Text Block] Calculation of Gain Name of the entity. Pfizer [Member] Name of the entity. Telavant Holdings, Inc [Member] Telavant Holdings, Inc. [Member] Telavant Holdings, Inc [Member] Name of business transaction. Roche Transaction [Member] Disposal Group [Abstract] Telavant Disposition [Abstract] Disposal Groups, Including Discontinued Operations, Calculation of Gain [Abstract] Calculation of Gain [Abstract] Amount classified as liabilities attributable to disposal group held for sale. Disposal Group, Liabilities Liabilities transferred Amount classified as assets attributable to disposal group held for sale. Disposal Group, Assets Assets sold Amount classified as net assets (liabilities) attributable to disposal group held for sale. Disposal Group, Net Assets (Liabilities) Net liabilities sold Disposal Group, Consideration [Abstract] Consideration [Abstract] The future milestone to be received from sale of assets. Future Milestone to be Received from Sale of Assets Consideration to be received from milestone The carrying amount of noncontrolling interest derecognized attributable to disposal group held for sale. Disposal Group, Noncontrolling Interest, Derecognized Value Carrying amount of noncontrolling interest derecognized Amount of consideration received for sale of assets. Consideration received for sale of Assets Total consideration Amount of upfront cash payment received for sale of assets. Upfront Cash Payment Received for Sale of Assets Upfront cash payment Amount of before tax of income (loss) from a disposal group. Income (Loss) from Disposal Group, before Income Tax Pretax loss Amount of lease cost recognized by lessee for operating lease contract. Operating Lease, Costs Total operating lease cost Earn-Out Shares, Public Warrants and Private Placement Warrants [Abstract] The entire disclosure of earn-out shares, public warrants and private placement warrants. Earn-Out Shares, Public Warrants and Private Placement Warrants [Text Block] Earn-Out Shares, Public Warrants and Private Placement Warrants Name of the acquiree. Genevant [Member] Genevant [Member] License, Milestone and Other Revenue [Abstract] License, Milestone and Other Revenue [Abstract] Non Refundable Upfront Payment Received Non Refundable Upfront Payment Received Upfront payment received Amount of potential milestone payment receivable. Potential Milestone Payment Receivable Contingent milestone payments The amount of payment received upon development milestone was achieved. Milestone Payments Amount Received Milestone payments received Name of the acquiree. Covant [Member] Covant [Member] Collaboration and License Agreement entered by the entity. Collaboration and License Agreement [Member] Collaboration and License Agreement [Member] The name of related party. Arbutus Biopharma Corporation [Member] Arbutus Biopharma Corporation [Member] Investments Disclosure [Abstract] Investments [Abstract] The name of combined merged entity. Ciox Parent [Member] Datavant Merger [Member] The Company's stock-based incentive compensation plan. Two015 Stock Based Incentive Compensation Plan [Member] RSL 2015 EIP [Member] The Roivant Sciences Ltd Equity Incentive Plan 2021 also known as (the "RSL 2021 EIP"). Roivant Sciences Ltd 2021 Equity Incentive Plan [Member] RSL 2021 EIP [Member] Grant date of Capped Value Appreciation Rights (CVARs). November 2021 Capped Value Appreciation Rights Grants [Member] November 2021 CVAR Grants [Member] November 2021 CVARs (Non-vested) [Member] Grant date of Capped Value Appreciation Rights (CVARs). March 2020 Capped Value Appreciation Rights Grants [Member] March 2020 CVAR Grants [Member] March 2020 CVARs [Member] Capped value appreciation rights to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period. Capped Value Appreciation Rights [Member] CVARs [Member] Amount of expense incurred for award modification under share-based payment arrangement. Share-Based Payment Arrangement, Award Modification Expense Award modification expense Number of fully service vested options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Service Vested , Outstanding, Number Number of service-vested shares (in shares) The number of equity instruments vested and settled during the period. Equity Instruments Vested and Settled, Shares Equity instruments vested and settled (in shares) Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time and Share-based payment arrangement awarded for meeting performance target. Stock Options and Performance Stock Options [Member] Stock Options and Performance Stock Options [Member] The intrinsic value of options exercised during the period. Intrinsic Value of Options Exercised Intrinsic value of options exercised Weighted average grant-date fair value of options granted. Sharebased Compensation Arrangement by Sharebased Payment Award, Options, Granted, Weighted Average Grant Date Fair Value Weighted-average grant date fair value per share of stock options granted (in dollars per share) Aggregate Intrinsic Value [Abstract] Equity incentive plan term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Equity Incentive Plan Term Equity incentive plan term The number of equity incentive plans for the company during the period. Number of Equity Incentive Plans Number of equity incentive plans The Roivant Sciences Ltd. 2021 Equity Incentive Plan (the "RSL 2021 EIP"), the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan, and the Roivant Sciences Ltd. Amended and Restated 2015 Restricted Stock Unit Plan (collectively, the "RSL Equity Plans"). Roivant Sciences Ltd Equity Plans [Member] RSL Equity Plans [Member] Performance stock units. Performance Stock Units [Member] Subsidiary equity incentive plans is a plan adopted by wholly owned and majority-owned or controlled subsidiaries of Roivant Sciences Ltd. Subsidiary Equity Incentive Plans [Member] Subsidiary Equity Incentive Plans [Abstract] Employee Stock Purchase Plan [Abstract] Percentage of stock purchase price equal to lower of closing price on first and last trading day of the offering period in which the eligible employees can buy shares under the Employee stock purchase plan. Percentage of Stock Purchase Price Equal to Lower of Closing Price Percentage of stock purchase price equal to lower of closing price under ESPP Percentage of maximum contribution of base salary an eligible employee can made under the employee stock purchase plan. Percentage of Maximum Contribution of Base Salary Percentage of maximum contribution of base salary Maximum amount of annual contribution an eligible employee can made under the employee stock purchase plan. Maximum Amount of Annual Contribution Maximum amount of contribution of base salary Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met and Share-based payment arrangement awarded for meeting performance target. Restricted Stock and Performance Stock Units [Member] Restricted Stock and Performance Stock Units [Member] Restricted Stock Units and Performance Stock Units (Non-vested) [Member] Tabular disclosure share based payment arrangement fair value of vested stock option and performance option. Schedule of Share Based Payment Arrangement Fair Value of Vested Stock Option and Performance Option [Table Text Block] Summary of Fair Value of Vested Stock Option Schedule Of Share Based Compensation Stock Options And Performance Options Activity. Schedule Of Share Based Compensation Stock Options And Performance Options Activity [Table Text Block] Summary of Stock Option Activity Tabular disclosure of Share Based Compensation Restricted Stock And Performance Stock Units Award Activity. Schedule Of Share Based Compensation Restricted Stock And Performance Stock Units Award Activity [Table Text Block] Activity for Restricted Stock Units and Performance Stock Units Name of equity incentive plan. Equity Incentive Plan 2015 [Member] Name of equity incentive plan. Equity Incentive Plan 2021 [Member] Tabular disclosure of the capped value appreciation rights stock units activity. Schedule of Capped Value Appreciation Rights Stock Units Activity [Table Text Block] Activity for Capped Value Appreciation Rights Tabular disclosure of useful life of long lived, physical assets used in the normal conduct of business and not intended for resale. Property and Equipment, Estimated Useful Life [Table Text Block] Estimated Useful Life Property And Equipments [Abstract] Property and Equipment [Abstract] Description of Business [Abstract] Description of Business [Abstract] Liquidity [Abstract] Liquidity [Abstract] Minimum age required for the topical treatment of atopic dermatitis. Minimum Age Required for Treatment Minimum age required for treatment The cash outflow associated with the warrant redemptions during period of the time. Payment for Warrant Redemptions Payment for redemptions of the Company's warrants Payment made during the period for achieving the milestone or milestones. Milestone Payments Milestone payments The cash outflow associated with payment for offering and loan costs during the period. Payment for Offering and Loan Costs Payment of offering costs and loan origination costs The cash inflow from the sale of assets. Proceeds from Sale of Assets Proceeds from sale of Telavant net assets, net The net cash inflows from issuance of subsidiary common shares, net of issuance costs paid. Proceeds from Issuance of Subsidiary Common Shares, Net Proceeds from issuance of subsidiary common shares, net of issuance costs paid Amount of expense or loss included in net income that result in no cash flow, classified as other. Noncash, Other Other Amount of cashless exercise of the company's common stock warrants in noncash investing or financing activities. Cashless Exercise of the Company Common Stock Warrants Cashless exercise of the Company's warrants The cash outflow for debt repayment of long-term debt and convertible debt by subsidiary during the period. Repayment of Long Term Debt and Convertible Debt by Subsidiary Repayment of debt by subsidiary The cash inflow associated with the aggregate amount received by the entity through subsidiary debt financings, net during the period. Proceeds from Subsidiary Debt Financings, Net Proceeds from subsidiary debt financings, net of financing costs paid Amount of common shares and other consideration issued for the purchase of property and equipment in noncash investing or financing activities. Common Shares and Other Consideration Issued for Purchase of Property and Equipment Issuance of the Company's common shares and other consideration for an acquisition Cash outflow in the form of capital distributions and subsidiary dividends to common shareholders, preferred shareholders and noncontrolling interests. Payments of Subsidiary Dividends Payment of subsidiary dividend The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. Non-Cash Acquired In-Process Research and Development Non-cash acquired in-process research and development Payments of Taxes for the Repurchase of Equity. Payments of Taxes for the Repurchase of Equity Taxes paid related to net settlement of equity awards Security that gives the holder the right to purchase one share of common stock at a specific exercise price. Private Placement Warrants [Member] Private Placement Warrants [Member] The other stock based awards and instruments issued related to the awards consisting of stock units. Other Stock Based Awards and Instruments Issued [Member] Other Stock Based Awards and Instruments Issued [Member] Share instrument of restricted common stock which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met. Restricted Common Stock [Member] Restricted Common Stock (Non-vested) [Member] In finance, a warrant is a security that entitles the holder to buy or sell stock, typically the stock of the issuing company, at a fixed price called the exercise price. Public Warrants [Member] Public Warrants [Member] Earnout or earn-out refers to a pricing structure in mergers and acquisitions where the sellers must "earn" part of the purchase price based on the performance of the business. Earn Out Shares Nonvested [Member] Earn-Out Shares (Non-vested) [Member] The cash outflow associated with the amount received from entity's raising of capital via private rather than public placement. Exercise of Private Placement Warrants Value Exercise of Private Placement Warrants Income Tax operating losses [Abstract] Income Tax Operating Losses [Abstract] Percentage of future taxable income for tax years and other net operating losses can be carried forward indefinitely as well, with an annual limitation on utilization. Annual Net Operating Loss Utilization Limitation Percentage Annual net operating loss utilization limitation percentage United States and Canada. United States And Canada [Member] United States and Canada [Member] For all equity method investments in an unrealized loss position, including those for which other-than-temporary impairments have not been recognized in earnings (including investments for which a portion of an other-than-temporary impairment has been recognized in other comprehensive income), a tabular disclosure of the aggregate related fair value of equity method investments with unrealized losses and the aggregate amount of unrealized losses (that is, the amount by which amortized cost basis exceeds fair value). Schedule of Unrealized Loss on Equity Method Investments [Table Text Block] Unrealized Losses (Gains) on Significant Equity Method Investments Tabular disclosure of financial information for equity method investments. Equity Method Investment, Summarized Financial Information [Table Text Block] Consolidated Financial Information The name of related party. Datavant Holdings, Inc [Member] Datavant [Member] The fair value of earn-out shares issued. Earnout Shares [Member] Earn-Out Shares [Member] The fair value of liability instruments measured at fair value. Liability Instruments Measured At Fair Value [Member] Liability Instruments Measured at Fair Value [Member] Each whole warrant exercisable for one Common Share at an exercise price of $11.50 per share. Redeemable Warrants [Member] Public Warrants [Member] Fair value of other liability instruments measured at fair value. Other Liability Instruments Measured At Fair Value Other liability instruments Schedule for earn-out shares, public warrants and private placement warrants. Earn-Out Shares, Public Warrants and Private Placement Warrants [Table] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Earn-Out Shares, Public Warrants and Private Placement Warrants [Line Items] Public Warrants and Private Placement Warrants [Abstract] Public Warrants and Private Placement Warrants [Abstract] The exercise price per Common Share on a cashless basis to exercise warrants. Exercise Price Cashless exercise price (in dollars per share) Number of cashless public warrants exercised during the period. Cashless Public Warrant Exercised Cashless warrant exercised (in shares) Earn-Out Shares [Abstract] Earn-Out Shares [Abstract] The number of trading days that are allowed to meet earn-out share price during vesting period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Number of Trading Days to be used to Meet Earn-Out Share Price Threshold Number of trading days to meet earn-out price threshold Number of earn-out shares vested during period. Number of Earn-Out Shares Vested Number of earn-out shares vested (in shares) Number of trading days allowed to calculate earnout share price during vesting period, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Number of Trading Days Allowed to Calculate Earn-Out Share Price Threshold Trading day period for earn-out shares The share price of earn-out share. Earn-Out Share Price Earn-out share price (in dollars per share) The collective percentage of earn-out shares. Percentage of Earn-Out Shares Percentage of earn-out shares Aggregate number of shares exchanged during the period. Stock Issued During Period Shares Cash Warrant Exercises Aggregate value of shares exchanged (in shares) The percentage of earnout shares. Twenty Percent Earn-Out Shares [Member] 20% Earn-Out [Member] Number of Public warrants cash exercised during the period. Public Warrant Cash Exercised Warrant exercised (in shares) Name of the sponsor company. Patient Square Capital Limited Liability Company [Member] MAAC Sponsor [Member] Aggregate number of shares exchanged on a cashless basis during the period. Stock Issued During Period Shares Cashless Warrant Exercises Aggregate value of shares exchanged on a cashless basis (in shares) Security that gives the holder the right to purchase one share of Class A common stock at a specific exercise price. Public Warrants and Private Placement Warrants [Member] Public and Private Warrants [Member] Number of trading days for common stock price to exceed threshold, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Number of Trading Days Number of trading days Period after the completion of a business combination when warrants will become exercisable, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Period to Exercise Warrants After Business Combination Period to exercise warrants after business combination Redemption price per share or per unit of warrants or rights outstanding. Class of Warrant or Right Redemption Price Redemption price (in dollars per share) Number of shares unexercised of warrant redeemed during the period. Class of Warrant or Right Unexercised Price of Warrants Unexercised public warrants (in shares) The percentage of earn-out shares. Ten Percent Earn-Out Shares [Member] 10 % Earn-Out [Member] Number of common shares issued to surrendering holder per warrant during the period. Stock Issued During Period Number of Shares Issued to Surrendering Holder Per Warrant Number of common shares issued to surrendering holder per warrant (in shares) The exercise price per common share on a cash basis to exercise warrants. Cash Exercise Price Cash exercise price (in dollars per share) Describe the conversion rate of preferred stock if preferred stock is convertible. Liquidation Preference, Conversion Rate Common Share Repurchase Program [Abstract] Common Share Repurchase Program [Abstract] This represents the number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. Number of Stock Repurchased During Period, Shares Number of shares repurchased (in shares) This represent the aggregate equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. Aggregate amount for Stock Repurchased During Period, Value Aggregate purchase price A program to buyback its own share. Stock Repurchase Program [Member] NovaQuest Agreement Amendment. NovaQuest Agreement Amendment [Member] Credit Facility Amendment. Credit Facility Amendment [Member] RIPSA Amendment. RIPSA Amendment [Member] Total required debt instrument quarterly payments made. Total Required Debt Instrument Quarterly Payments Made. Periodic payment The name of related party. Sumitomo [Member] Amount represents the aggregate remaining milestone payment obligation under the NovaQuest Agreement Amendment. Aggregate Remaining Milestone Payment Obligation Aggregate remaining milestone payment obligation to be paid Royalties currently payable over the next twelve months. Royalties Currently Payable, Next twelve Months Royalties Currently Payable 2025 Royalties currently payable over the next two years. Royalties Currently Payable, Year Two Royalties Currently Payable 2026 Royalties currently payable over the next three years. Royalties Currently Payable, Year Three Royalties Currently Payable 2027 Commitment amount to Dermavant in exchange for convertible preferred shares with a 1.5x liquidation preference on invested capital. Commitment Amount in Exchange for Convertible Preference Shares Commitment amount Third party ownership of subsidiary. Third Party Ownership of Subsidiary Percentage Third party ownership of subsidiary Fair Value Measurement Inputs and Valuation Techniques [Abstract] Fair Value Measurement Inputs and Valuation Techniques [Abstract] Fair value asset, measurement input. Fair Value Asset, Measurement Input Investment in equity securities, measurement input The earn-out share redemption trigger price. Earn-Out Share Redemption Trigger Price Share redemption trigger price (in dollars per share) The fair value measurement input for Earn-out shares. Fair Value Earnout Shares Measurement Input Earn-out share, measurement input Unrealized Losses (Gains) on Significant Equity Method Investments [Abstract] Unrealized Losses (Gains) on Significant Equity Method Investments [Abstract] Significant Equity Method Investments [Abstract] Significant Equity Method Investments [Abstract]